NGL Fine-Chem Limited (NGLFINE.BO)
INR 2040.15
(2.62%)
INR 2040.15
(2.62%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 3.38 Billion INR | 21.79% |
| 2022 | 2.78 Billion INR | -12.42% |
| 2021 | 3.17 Billion INR | 24.51% |
| 2020 | 2.55 Billion INR | 71.19% |
| 2019 | 1.48 Billion INR | -1.21% |
| 2018 | 1.5 Billion INR | 35.91% |
| 2017 | 1.1 Billion INR | 15.53% |
| 2016 | 960.27 Million INR | -0.28% |
| 2015 | 962.92 Million INR | 9.02% |
| 2014 | 883.27 Million INR | 11.99% |
| 2013 | 788.68 Million INR | 41.93% |
| 2012 | 555.68 Million INR | 53.89% |
| 2011 | 361.08 Million INR | 2.06% |
| 2010 | 353.77 Million INR | 27.15% |
| 2009 | 278.23 Million INR | 12.97% |
| 2008 | 246.29 Million INR | 94.83% |
| 2007 | 126.41 Million INR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 907.53 Million INR | -9.03% |
| 2023 Q4 | 997.6 Million INR | 13.43% |
| 2023 FY | 3.38 Billion INR | 21.79% |
| 2023 Q1 | 710.42 Million INR | -8.71% |
| 2023 Q2 | 801.78 Million INR | 12.86% |
| 2023 Q3 | 879.51 Million INR | 9.7% |
| 2022 Q1 | 652.5 Million INR | -15.66% |
| 2022 Q3 | 719.34 Million INR | 6.23% |
| 2022 Q2 | 677.15 Million INR | 3.78% |
| 2022 Q4 | 778.22 Million INR | 8.18% |
| 2022 FY | 2.78 Billion INR | -12.42% |
| 2021 Q3 | 811.36 Million INR | 3.54% |
| 2021 Q4 | 773.69 Million INR | -4.64% |
| 2021 Q1 | 758.62 Million INR | 5.91% |
| 2021 FY | 3.17 Billion INR | 24.51% |
| 2021 Q2 | 783.65 Million INR | 3.3% |
| 2020 FY | 2.55 Billion INR | 71.19% |
| 2020 Q2 | 683.43 Million INR | 61.31% |
| 2020 Q4 | 716.26 Million INR | -1.5% |
| 2020 Q3 | 727.19 Million INR | 6.4% |
| 2020 Q1 | 423.68 Million INR | 26.01% |
| 2019 FY | 1.48 Billion INR | -1.21% |
| 2019 Q4 | 336.22 Million INR | -10.15% |
| 2019 Q1 | 406.99 Million INR | -4.29% |
| 2019 Q3 | 374.22 Million INR | 0.57% |
| 2019 Q2 | 372.1 Million INR | -8.57% |
| 2018 Q4 | 425.21 Million INR | 23.35% |
| 2018 FY | 1.5 Billion INR | 35.91% |
| 2018 Q2 | 389.2 Million INR | 10.27% |
| 2018 Q1 | 352.94 Million INR | 10.24% |
| 2018 Q3 | 344.73 Million INR | -11.43% |
| 2017 Q2 | 289.05 Million INR | 36.92% |
| 2017 Q4 | 320.16 Million INR | 9.32% |
| 2017 FY | 1.1 Billion INR | 15.53% |
| 2017 Q3 | 292.87 Million INR | 1.32% |
| 2017 Q1 | 211.12 Million INR | -18.28% |
| 2016 Q1 | 240.72 Million INR | -7.37% |
| 2016 FY | 960.27 Million INR | -0.28% |
| 2016 Q3 | 250.64 Million INR | 20.51% |
| 2016 Q4 | 258.36 Million INR | 3.08% |
| 2016 Q2 | 207.99 Million INR | -13.6% |
| 2015 Q1 | 246.5 Million INR | -2.28% |
| 2015 Q3 | 227.01 Million INR | -1.17% |
| 2015 Q4 | 259.87 Million INR | 14.47% |
| 2015 FY | 962.92 Million INR | 9.02% |
| 2015 Q2 | 229.71 Million INR | -6.81% |
| 2014 Q2 | 231.45 Million INR | 11.8% |
| 2014 Q4 | 252.26 Million INR | 31.26% |
| 2014 FY | 883.27 Million INR | 11.99% |
| 2014 Q1 | 207.03 Million INR | -0.69% |
| 2014 Q3 | 192.18 Million INR | -16.97% |
| 2013 Q2 | 195.33 Million INR | -6.36% |
| 2013 Q4 | 208.46 Million INR | 18.27% |
| 2013 FY | 788.68 Million INR | 41.93% |
| 2013 Q3 | 176.26 Million INR | -9.77% |
| 2013 Q1 | 208.59 Million INR | 22.62% |
| 2012 Q1 | 126.13 Million INR | 17.44% |
| 2012 FY | 555.68 Million INR | 53.89% |
| 2012 Q4 | 170.11 Million INR | 17.9% |
| 2012 Q3 | 144.29 Million INR | 25.33% |
| 2012 Q2 | 115.13 Million INR | -8.72% |
| 2011 Q3 | 94.79 Million INR | 0.0% |
| 2011 Q4 | 107.39 Million INR | 13.3% |
| 2011 FY | 361.08 Million INR | 2.06% |
| 2010 FY | 353.77 Million INR | 27.15% |
| 2009 FY | 278.23 Million INR | 12.97% |
| 2008 Q4 | 77.87 Million INR | 0.0% |
| 2008 FY | 246.29 Million INR | 94.83% |
| 2007 FY | 126.41 Million INR | 0.0% |
| 2007 Q4 | 35.58 Million INR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Abbott India Limited | 58.48 Billion INR | 94.209% |
| Cipla Limited | 257.74 Billion INR | 98.686% |
| Gland Pharma Limited | 56.41 Billion INR | 93.997% |
| GlaxoSmithKline Pharmaceuticals Limited | 34.53 Billion INR | 90.193% |
| Kopran Limited | 6.14 Billion INR | 44.892% |
| Marksans Pharma Limited | 21.77 Billion INR | 84.445% |
| Pfizer Limited | 21.93 Billion INR | 84.557% |
| Sanofi India Limited | 28.51 Billion INR | 88.121% |
| SMS Pharmaceuticals Limited | 7.06 Billion INR | 52.058% |